extenderBio

ExtenderBio is a biotechnology company specializing in the development of protein-based therapeutics. Founded in 2010, the company is headquartered in Cambridge, Massachusetts, and operates globally. ExtenderBio's primary focus is on creating extended half-life proteins, which are designed to remain active in the body for longer periods than traditional proteins. This is achieved through the use of proprietary technologies that modify the protein structure, enhancing its stability and duration of action.

The company's portfolio includes a range of therapeutic candidates targeting various diseases, including cancer, infectious diseases, and metabolic disorders. ExtenderBio's approach aims to improve patient outcomes by providing more effective and longer-lasting treatments. The company's technology platform is based on the use of engineered proteins that can be modified to have extended half-lives, making them more potent and reducing the frequency of administration required.

ExtenderBio has received significant investment from venture capital firms and has established partnerships with major pharmaceutical companies to advance its drug development pipeline. The company's scientific team consists of experts in protein engineering, biochemistry, and pharmacology, ensuring a robust foundation for its research and development efforts. ExtenderBio's mission is to revolutionize the field of protein therapeutics by providing innovative solutions that address unmet medical needs.